obinutinib

Obinutinib is a glycoengineered, type II, anti-CD20 monoclonal antibody designed to treat B-cell malignancies such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. Developed by Glycart Biotechnology (a Roche subsidiary), it targets the CD20 antigen on B cells to induce cell death through enhanced antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis induction. Unlike type I anti-CD20 antibodies like rituximab, obinutinib's Fc region is afucosylated to increase its affinity for FcyRIIIa receptors on effector cells, thereby boosting its immune-mediated killing capacity. It is frequently used in combination with other targeted therapies, such as venetoclax, or with chemotherapy to achieve deep molecular remissions in patients with hematologic cancers.

Brand names

GazyvaGazyvaro

Other names

obinutinibum